Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Current Assets (2023 - 2025)

Immunome (IMNM) has disclosed Current Assets for 3 consecutive years, with $660.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 198.54% year-over-year to $660.8 million, compared with a TTM value of $660.8 million through Dec 2025, up 198.54%, and an annual FY2025 reading of $660.8 million, up 198.54% over the prior year.
  • Current Assets was $660.8 million for Q4 2025 at Immunome, up from $279.9 million in the prior quarter.
  • Across five years, Current Assets topped out at $660.8 million in Q4 2025 and bottomed at $39.5 million in Q2 2023.
  • Average Current Assets over 3 years is $243.9 million, with a median of $260.7 million recorded in 2024.
  • The sharpest move saw Current Assets soared 619.23% in 2024, then dropped 2.41% in 2025.
  • Year by year, Current Assets stood at $144.7 million in 2023, then surged by 52.96% to $221.3 million in 2024, then soared by 198.54% to $660.8 million in 2025.
  • Business Quant data shows Current Assets for IMNM at $660.8 million in Q4 2025, $279.9 million in Q3 2025, and $277.4 million in Q2 2025.